Is natalizumab a breakthrough in the treatment of multiple sclerosis?
@article{Doggrell2003IsNA, title={Is natalizumab a breakthrough in the treatment of multiple sclerosis?}, author={S. Doggrell}, journal={Expert Opinion on Pharmacotherapy}, year={2003}, volume={4}, pages={1001 - 999} }
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated… CONTINUE READING
Topics from this paper
5 Citations
Oxidative Stress and Lymphocyte Alterations in Chronic Relapsing Experimental Allergic Encephalomyelitis in the Rat Hippocampus and Protective Effects of an Ethanolamine Phosphate Salt
- Chemistry, Medicine
- Molecular Neurobiology
- 2019
- 1
- PDF
Massenspektrometrisches Fragmentierungsverhalten oxidierter schwefelhaltiger Aminosäuren und ihr Nutzen für die Proteomforschung
- Chemistry
- 2009
- PDF
References
SHOWING 1-10 OF 16 REFERENCES
A controlled trial of natalizumab for relapsing multiple sclerosis.
- Medicine
- The New England journal of medicine
- 2003
- 1,151
- PDF
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
- Medicine
- The Lancet
- 1998
- 1,733
Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
- Medicine
- Archives of internal medicine
- 2002
- 86
- PDF
Interferons in relapsing remitting multiple sclerosis: a systematic review
- Medicine
- The Lancet
- 2003
- 295
- PDF
A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.
- Medicine
- Clinical therapeutics
- 2002
- 50
- Highly Influential
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
- Medicine
- Annals of neurology
- 2001
- 724
A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis
- Biology
- Journal of Neuroimmunology
- 1995
- 187